About Icosavax
Icosavax is a company based in Seattle (United States) founded in 2017 by Adam Simpson was acquired by Astrazeneca in December 2023.. Icosavax has raised $152 million across 3 funding rounds from investors including Astrazeneca, Citadel and Janus Henderson Investors. The company has 60 employees as of December 31, 2022. Icosavax operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Seattle, United States
- Employees 60 as on 31 Dec, 2022
- Founders Adam Simpson
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Icosavax, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$152 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Series B
Apr 07, 2021
-
Investors
Astrazeneca
& 13 more
-
Employee Count
60
as on Dec 31, 2022
-
Acquired by
Astrazeneca
(Dec 12, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Icosavax
Icosavax has successfully raised a total of $152M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $100.0M
-
First Round
First Round
(03 Oct 2019)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Series B - Icosavax | Valuation | RA Capital Management | |
| Oct, 2020 | Amount | Grant - Icosavax | Valuation |
investors |
|
| Oct, 2019 | Amount | Series A - Icosavax | Valuation | Qiming |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Icosavax
Icosavax has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Citadel and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Icosavax
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Icosavax
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Icosavax Comparisons
Competitors of Icosavax
Icosavax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Icosavax
Frequently Asked Questions about Icosavax
When was Icosavax founded?
Icosavax was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Icosavax located?
Icosavax is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Icosavax?
Adam Simpson is the current CEO of Icosavax. They have also founded this company.
Is Icosavax a funded company?
Icosavax is a funded company, having raised a total of $152M across 3 funding rounds to date. The company's 1st funding round was a Series A of $52M, raised on Oct 03, 2019.
How many employees does Icosavax have?
As of Dec 31, 2022, the latest employee count at Icosavax is 60.
What does Icosavax do?
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
Who are the top competitors of Icosavax?
Icosavax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Who are Icosavax's investors?
Icosavax has 14 investors. Key investors include Astrazeneca, Citadel, Janus Henderson Investors, RA Capital, and Qiming Venture Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.